drugset / Trial / NCT02140554

A Study Evaluating the Safety and Efficacy of Lovo-cel in Severe Sickle Cell Disease

NCT02140554 ↗

Phase 1/2 Completed 54 enrolled Genetix Biotherapeutics Inc.
Non-randomizedParallel-groupOpen-labelTreatment

Summary

This is a non-randomized, open label, multi-site, single dose, Phase 1/2 study in approximately 50 adults and adolescents with severe SCD. The study will evaluate hematopoietic stem cell and progenitor stem cell (collectively referred to as hematopoietic stem and progenitor cells or HSPCs) transplantation using lovo-cel.

Timeline

Start
2015-02-02
Primary completion
2023-07-31
Completion
2024-01-30

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject lovo-cel Unknown — Intravenous

Indications